Per KFF 2025, 43% of firms with 5,000-plus employees cover weight-loss GLP-1s (up from 28%), but only 30% of firms with 1,000 to 4,999 employees and 16% of firms with 200 to 999
Cardiovascular Fitness Optimizing endurance for fat-burning efficiency
These medications must be prescribed and supervised by licensed healthcare providers
Before we dive into my current maintenance journey, I think it might be helpful to share some context on where Ive come from
Segments Covered in the Report By Product Type Injectables: [Exenatide(Byetta, Bydureon), Liraglutide(Victoza, Saxenda), Semaglutide(Ozempic, Wegovy), Dulaglutide(Trulicity), Lixisenatide(Lyxumia), Albiglutide (Eperzan)] Oral GLP-1 Receptor Agonists: [Rybelsus (Semaglutide oral)] By Application Type 2 Diabetes Management Obesity and Weight Management Cardiovascular Diseases (CV) By End User Hospitals Clinics Retail Pharmacies Homecare/Direct-to-Patient By Distribution Channel Retail Pharmacies Online Pharmacies Hospitals & Clinics Set up a meeting at your convenience to get more insights instantly!
Its incumbent on employers now to start navigating how to cover the drugs in the most cost-effective manner. Editors Note: Additional Content For more information and resources related to this article, see the pages below, which offer quick access to all WorldatWork content on these topics: